ALK and non-small cell lung carcinoma: Based on the results of this trial, the FDA approved lorlatinib for patients with ALK-rearranged advanced NSCLC progressing on crizotinib and at least one other ALK-TKI, or after first-line treatment with non-crizotinib ALK-TKI, in November 2018.